预测从轻度认知障碍转化为阿尔茨海默病的预测:一种多式模式的方法
Daniel Agostinho1,2,3, Marco Simões1,2,3, Miguel Castelo-Branco1,3
1Coimbra Institute for Biomedical Imaging and Translational Research (CIBIT), ICNAS, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal.
Brain communications
|July 4, 2024
概括
在轻度认知障碍患者中预测阿尔茨海默病的进展至关重要. 佛罗贝塔皮尔PET显示了最高的准确性,而MRI与氧糖糖PET相结合显示了协同的预测能力.
科学领域:
- 神经科学是一个神经科学.
- 医疗成像医学成像
- 机器学习 机器学习
背景情况:
- 预测阿尔茨海默病 (AD) 从轻度认知障碍 (MCI) 的进展是临床上对早期干预至关重要的.
- 神经成像生物标志物越来越多地被认为具有预测MCI转化为AD的潜力.
- 现有的方法往往专注于单一的模式,限制了全面的预测能力.
研究的目的:
- 评估MCI转化为AD的单个和组合神经成像模式的预测性能.
- 探索多模式成像在预测阿尔茨海默病进展中的协同效应.
- 识别与早期阿尔茨海默病理学相关的新型成像生物标志物.
主要方法:
- 对来自阿尔茨海默氏病神经成像计划的480名MCI患者的数据应用了多模式方法.
- 图像成像方法包括MRI,氧葡萄糖PET,FlorbetapirPET和扩散张力成像.
- 机器学习模型是使用基于图谱的兴趣区域特征构建的,用于多模式分析的重量融合组合.
主要成果:
- 单一模式分析显示,Florbetapir PET在预测转换方面获得了最高的平衡精度 (83.51%).
- 核磁共振和氧葡萄糖PET的组合显示出有希望的协同预测能力 (平衡精度为78.43%).
- 大脑干被确定为MRI和氧葡萄糖PET的敏感生物标志物,而体和相邻的皮质区域显示出潜在的潜力.
结论:
- 佛罗贝塔皮尔PET (反射β-粉胺) 对MCI转化为AD提供了强大的预测价值.
- 多模式成像,特别是MRI和氧糖PET,可以通过协同效应提高预测准确性.
- 识别特定的大脑区域,如大脑干和体,可能有助于早期发现和理解阿尔茨海默病.
更多相关视频
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
7.9K
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.0K
相关概念视频
Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
Alzheimer's Disease: Treatment
177
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
177
